Kanuma FDA Approval History
FDA Approved: Yes (First approved December 8, 2015)
Brand name: Kanuma
Generic name: sebelipase alfa
Dosage form: Injection
Company: Alexion Pharmaceuticals, Inc.
Treatment for: Lysosomal Acid Lipase Deficiency
Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).
Development timeline for Kanuma
| Date | Article |
|---|---|
| Dec 8, 2015 | Approval FDA Approves Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency |
| Sep 6, 2015 | Alexion Receives Notification of PDUFA Date Extension for Kanuma (sebelipase alfa) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
